These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 37716372)
21. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234 [TBL] [Abstract][Full Text] [Related]
22. External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3-F4 patients. Carvalho-Gomes Â; Valcheva Valcheva TV; Sahuco I; Vidal E; Martínez-Arenas L; Vinaixa C; Aguilera V; García García S; Berenguer M United European Gastroenterol J; 2024 Sep; 12(7):901-910. PubMed ID: 38720450 [TBL] [Abstract][Full Text] [Related]
23. Decision tree algorithm predicts hepatocellular carcinoma among chronic hepatitis C patients following viral eradication. Lu MY; Liu TW; Liang PC; Huang CI; Tsai YS; Tsai PC; Ko YM; Wang WH; Lin CC; Chen KY; Wang SC; Wei YJ; Hsu PY; Jang TY; Hsieh MY; Wang CW; Yeh ML; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML Am J Cancer Res; 2023; 13(1):190-203. PubMed ID: 36777503 [TBL] [Abstract][Full Text] [Related]
24. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response. Toyoda H; Tada T; Yasuda S; Mizuno K; Ito T; Kumada T Clin Infect Dis; 2020 Mar; 70(6):1208-1214. PubMed ID: 31056696 [TBL] [Abstract][Full Text] [Related]
25. Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma. Li X; Bao H; Shi Y; Zhu W; Peng Z; Yan L; Chen J; Shu X Medicine (Baltimore); 2023 Nov; 102(45):e35892. PubMed ID: 37960763 [TBL] [Abstract][Full Text] [Related]
26. Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication. Ohta A; Ogawa E; Murata M; Matsumoto Y; Yamasaki S; Ikezaki H; Furusyo N J Med Virol; 2022 Oct; 94(10):5007-5014. PubMed ID: 35652276 [TBL] [Abstract][Full Text] [Related]
27. Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan. Toyoda H; Tada T; Tsuji K; Hiraoka A; Tachi Y; Itobayashi E; Takaguchi K; Senoh T; Takizawa D; Ishikawa T; Kumada T Hepatol Res; 2016 Jul; 46(8):734-42. PubMed ID: 26508201 [TBL] [Abstract][Full Text] [Related]
28. External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population. Åström H; Ndegwa N; Hagström H JHEP Rep; 2021 Oct; 3(5):100343. PubMed ID: 34611618 [TBL] [Abstract][Full Text] [Related]
29. Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals. Ogawa E; Nakamuta M; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Ooho A; Azuma K; Takahashi K; Satoh T; Koyanagi T; Yamashita N; Ichiki Y; Yamashita N; Kuniyoshi M; Yanagita K; Amagase H; Morita C; Sugimoto R; Kato M; Shimoda S; Nomura H; Hayashi J; J Gastroenterol Hepatol; 2022 Jan; 37(1):190-199. PubMed ID: 34374128 [TBL] [Abstract][Full Text] [Related]
30. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Yasui Y; Kurosaki M; Komiyama Y; Takada H; Tamaki N; Watakabe K; Okada M; Wang W; Shimizu T; Kubota Y; Higuchi M; Takaura K; Tsuchiya K; Nakanishi H; Takahashi Y; Itakura J; Enomoto N; Izumi N Hepatol Res; 2018 Dec; 48(13):1131-1139. PubMed ID: 30030872 [TBL] [Abstract][Full Text] [Related]
31. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. Miki D; Akita T; Kurisu A; Kawaoka T; Nakajima T; Hige S; Karino Y; Toyoda H; Kumada T; Tsuge M; Hiramatsu A; Imamura M; Aikata H; Hayes CN; Honda K; Seike M; Akuta N; Kobayashi M; Kumada H; Tanaka J; Chayama K J Gastroenterol; 2020 Dec; 55(12):1162-1170. PubMed ID: 33057914 [TBL] [Abstract][Full Text] [Related]
32. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803 [TBL] [Abstract][Full Text] [Related]
33. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. Tahata Y; Sakamori R; Yamada R; Kodama T; Hikita H; Hagiwara H; Imai Y; Hiramatsu N; Tamura S; Yamamoto K; Oshita M; Ohkawa K; Hijioka T; Fukui H; Ito T; Doi Y; Yamada Y; Yakushijin T; Yoshida Y; Tatsumi T; Takehara T; Aliment Pharmacol Ther; 2021 Nov; 54(10):1340-1349. PubMed ID: 34618934 [TBL] [Abstract][Full Text] [Related]
34. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C. Yamashita Y; Joshita S; Sugiura A; Yamazaki T; Kobayashi H; Wakabayashi SI; Yamada Y; Shibata S; Kunimoto H; Iwadare T; Matsumura M; Miyabayashi C; Okumura T; Ozawa S; Nozawa Y; Kobayashi N; Komatsu M; Fujimori N; Saito H; Umemura T Hepatol Res; 2021 Sep; 51(9):933-942. PubMed ID: 34216422 [TBL] [Abstract][Full Text] [Related]
35. Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. Minami T; Tateishi R; Fujiwara N; Nakagomi R; Nakatsuka T; Sato M; Uchino K; Enooku K; Nakagawa H; Fujinaga H; Izumiya M; Hanajiri K; Asaoka Y; Kondo Y; Tanaka Y; Otsuka M; Ohki T; Arai M; Tanaka A; Yasuda K; Miura H; Ogata I; Kamoshida T; Inoue K; Koike Y; Akamatsu M; Mitsui H; Fujie H; Ogura K; Yoshida H; Wada T; Kurai K; Maekawa H; Obi S; Teratani T; Masaki N; Nagashima K; Ishikawa T; Kato N; Moriya K; Yotsuyanagi H; Koike K Liver Cancer; 2021 Jul; 10(4):309-319. PubMed ID: 34414119 [TBL] [Abstract][Full Text] [Related]
36. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834 [TBL] [Abstract][Full Text] [Related]
37. Use of survival support vector machine combined with random survival forest to predict the survival of nasopharyngeal carcinoma patients. Xiao Z; Song Q; Wei Y; Fu Y; Huang D; Huang C Transl Cancer Res; 2023 Dec; 12(12):3581-3590. PubMed ID: 38192980 [TBL] [Abstract][Full Text] [Related]
38. Derivation and validation of machine learning models for preoperative estimation of microvascular invasion risk in hepatocellular carcinoma. Chen Z; Zuo X; Zhang Y; Han G; Zhang L; Ding W; Wu J; Wang X Ann Transl Med; 2023 Mar; 11(6):249. PubMed ID: 37082689 [TBL] [Abstract][Full Text] [Related]
39. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV. Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087 [TBL] [Abstract][Full Text] [Related]
40. Development of a nomogram to predict the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis on antivirals. Shi K; Li P; Zhang Q; Zhang Y; Bi Y; Zeng X; Wang X Front Oncol; 2023; 13():1128062. PubMed ID: 36874109 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]